
    
      Subjects will undergo screenibg period of up to two weeks. Following to eligibilidy
      confirmation subjects will be randomized into one of the two treatment groups and treated
      with study device once daily for 4 weeks.

      Continuation of study device for additional period is based on wound healing progression and
      under investigator's discretion.

      Subjects will be followed up weekly following to 4 weeks of active treatment for additional 8
      weeks untol week 12.
    
  